Filing Flows › Dianthus Therapeutics (DNTH) › Q4 2025
Dianthus Therapeutics (DNTH) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 9, 2026
Dianthus Therapeutics (DNTH) reported revenue of $284K for the fourth quarter 2025 (Q4 2025), -79% from a year earlier and -28% from the quarter before.
Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year), net loss $64.4M, operating cash flow −$47.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $284K | -28% | -79% |
| Operating profit | −$69.5M | — | — |
| Net earnings | −$64.4M | — | — |
| Operating cash flow | −$47.0M | — | — |
What changed
Revenue was $284K in Q4 2025, down 79% year over year and down 28% from the previous quarter.
Operating costs exceeded revenue by $69.5M, an operating margin of -24486.3%. Total costs grew 110% against a revenue fall of 79%. The fastest-growing cost line was Research & development (+127%). The quarter ended with a net loss of $64.4M, wider than the previous quarter's $36.8M loss.
Operating cash flow was −$47.0M. Non-cash charges added back $27K of depreciation and $6.0M of share-based compensation. Working capital and other items added $11.4M. Capital expenditures of $138K exceeded it, leaving free cash flow of −$47.1M.
Questions
What was Dianthus Therapeutics' revenue in the fourth quarter 2025?
Dianthus Therapeutics (DNTH) reported revenue of $284K for the fourth quarter 2025 (Q4 2025), -79% from a year earlier and -28% from the quarter before.